Quinupristin-dalfopristin resistance in Streptococcus pneumoniae: Novel L22 ribosomal protein mutation in two clinical isolates from the SENTRY antimicrobial surveillance program

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 8, 2003, Pages 2696-2698

  Jones, Ronald N ^a   Farrell, David J ^b   Morrissey, Ian ^b  

^a JMI LABORATORIES   (United States)

^b GR Micro Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; AMOXICILLIN PLUS CLAVULANIC ACID; CEFEPIME; CEFTRIAXONE; CEFUROXIME; CHLORAMPHENICOL; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DOXYCYCLINE; ERYTHROMYCIN; GARENOXACIN; GATIFLOXACIN; GENE PRODUCT; LEVOFLOXACIN; LINEZOLID; PENICILLIN G; PROTEIN RPLV; RIBOSOME PROTEIN; RIFAMPICIN; TELITHROMYCIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; GENE DUPLICATION; GENE MUTATION; GENE SEQUENCE; GRAM POSITIVE COCCI; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RIBOSOME; SEQUENCE ANALYSIS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; BASE SEQUENCE; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, BACTERIAL; GREAT BRITAIN; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; PNEUMONIA, PNEUMOCOCCAL; POPULATION SURVEILLANCE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBOSOMAL PROTEINS; RNA-BINDING PROTEINS; STREPTOCOCCUS PNEUMONIAE; VIRGINIAMYCIN;

EID: 0041767391     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.8.2696-2698.2003     Document Type: Article

References (12)

1. Appelbaum, P. C. 2002. Resistance among Streptococcus pneumoniae: implications for drug selection. Clin. Infect. Dis. 34:1613-1620.
2. Ballow, C. H., R. N. Jones, D. J. Biedenbach, and the North American ZAPS Research Group. 2002. A multicenter evaluation of linezolid antimicrobial activity in North America. Diagn. Microbiol. Infect. Dis. 43:75-83.
3. Bronzwaer, S. L. A. M., O. Cars, U. Buchholz, S. Molstad, W. Goettsch, I. K. Veldhuijzen, J. L. Kool, M. J. W. Sprenger, J. E. Degener, and the European Antimicrobial Resistance Surveillance System. 2002. A European study on the relationship between antimicrobial use and antimicrobial resistance. Emerg. Infect. Dis. 8:278-282.
4. Farrell, D. J., I. Morrissey, S. Bakker, and D. Felmingham. 2001. Detection of macrolide resistance mechanisms in Streptococcus pneumoniae and Streptoccus pyogenes using a multiplex rapid cycle PCR with microwell-format probe hybridization. J. Antimicrob. Chemother. 48:541-544.
5. Hoban, D. J., G. V. Doern, A. C. Fluit, M. Roussel-Delvallez, and R. N. Jones. 2001. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin. Infect. Dis. 32(Suppl. 2):S81-S93.
6. Jones, R. N., C. H. Ballow, D. J. Biedenbach, and The ZAPS Study Group Medical Centers. 2001. Multi-laboratory assessment of the linezolid spectrum of activity using the Kirby-Bauer disk diffusion method: Report of the Zyvox® Antimicrobial Potency Study (ZAPS) in the United States. Diagn. Microbiol. Infect. Dis. 40:59-66.
7. Low, D. E. 2002. The era of antimicrobial resistance - implications for the clinical laboratory. Clin. Microbiol. Infect. 8(Suppl. 3):9-20.
8. Leclercq, R. 2002. Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. Clin. Infect. Dis. 34:482-492.
9. Malbruny, B., A. Canu, B. Bozdogan, B. Fantin, I. Zarrouk, S. Dutka-Maten, C. Feger, and R. Leclercq. 2002. Resistance to quinupristin-dalfopristin due to mutation of L22 ribosomal protein in Staphylococcus aureus. Antimicrob. Agents Chemother. 46:2200-2207.
10. Musber, D. M., M. E. Dowell, V. D. Sbortridge, J. H. Jorgensen, P. Le Magueres, and K. L. Krause. 2002. Emergence of macrolide resistance during treatment of pneumococcal pneumonia. N. Engl. J. Med. 346:630-631.
11. NCCLS. 2000. Methods for dilution antimicrobial tests for bacteria that grows aerobically. Approved standard M7-A5. NCCLS, Wayne, Pa.
12. NCCLS. 2002. Performance standards for antimicrobial susceptibility testing. Supplemental tables, M100-S12. NCCLS, Wayne, Pa.